Clario Executive and Leadership Team

Richard Kohinga, the Chief Executive Officer at Clario, directs the company's overarching strategy and operational execution. Kohinga's leadership focuses on advancing Clario's mission to deliver leading endpoint technology solutions for clinical trials, ensuring seamless integration of scientific expertise and global scale. This involves driving the development and deployment of the comprehensive endpoint technology platform that empowers pharmaceutical, biotechnology, and medical device partners. Richard Kohinga's strategic vision guides the company's Trial Anywhere approach, facilitating rich clinical evidence generation across decentralized, hybrid, and site-based trial models. The Chief Executive Officer's oversight extends to fostering innovation and maintaining Clario's commitment to high-quality clinical evidence delivery across North America, Europe, and the Asia Pacific region.

Christopher Fikry, the President & Chief Executive Officer at Clario, spearheads the company's strategic direction and global operations. Fikry's role involves guiding Clario's commitment to transforming lives through advanced endpoint technology solutions for clinical trials. This leadership encompasses driving the integration of scientific expertise with global scale to deliver a comprehensive platform that supports pharmaceutical, biotechnology, and medical device partners. Christopher Fikry champions the Trial Anywhere approach, enabling the generation of robust clinical evidence across decentralized, hybrid, and site-based trial models. The President & Chief Executive Officer's focus remains on ensuring Clario's continued delivery of high-quality clinical evidence, leveraging decades of experience across North America, Europe, and the Asia Pacific region.

Nate Goldenman, the President & Chief Executive Officer at Clario, drives the strategic vision and operational framework for the organization. Goldenman's leadership is centered on advancing Clario's position as a provider of leading endpoint technology solutions for clinical trials, fusing scientific acumen with global reach. This involves overseeing the comprehensive endpoint technology platform that enables pharmaceutical, biotechnology, and medical device partners to achieve critical regulatory approvals and transform lives. Nate Goldenman's strategic initiatives support the Trial Anywhere methodology, facilitating the collection of rich clinical evidence across decentralized, hybrid, and site-based trial designs. The President & Chief Executive Officer's mandate includes ensuring the consistent delivery of high-quality clinical evidence across Clario's global presence in North America, Europe, and the Asia Pacific.

Joshua Collins, the Chief Executive Officer & Founder at Clario, established the company's foundational vision for endpoint technology in clinical trials. Collins' ongoing leadership directs the strategic evolution of Clario's comprehensive platform, integrating deep scientific expertise with extensive global operational capabilities. This involves guiding the company's commitment to empowering pharmaceutical, biotechnology, and medical device partners to achieve regulatory success and improve patient outcomes. Joshua Collins champions the Trial Anywhere approach, fostering the generation of rich clinical evidence across decentralized, hybrid, and site-based trial models. The Chief Executive Officer & Founder's influence ensures Clario's sustained delivery of high-quality clinical evidence, drawing on decades of experience across North America, Europe, and the Asia Pacific.

Holly Oliver, the Chief Financial Officer at Clario, directs the company's financial strategy and fiscal management. Oliver's leadership ensures the financial health and sustainability of Clario's operations, supporting its mission to deliver leading endpoint technology solutions for clinical trials. This involves managing financial resources to enable the fusion of scientific expertise and global scale into a comprehensive endpoint technology platform. Holly Oliver's financial oversight supports pharmaceutical, biotechnology, and medical device partners in their pursuit of regulatory approvals and life-transforming advancements. The Chief Financial Officer's role is critical in maintaining the financial integrity of the Trial Anywhere approach and ensuring the consistent delivery of high-quality clinical evidence across North America, Europe, and the Asia Pacific.

Alexander Brito, the Chief Financial Officer, Rei Bookkeeping & Fractional Services at Clario, leads the financial operations and strategic fiscal planning for specialized bookkeeping and fractional services. Brito's expertise ensures robust financial management, supporting Clario's broader mission of delivering advanced endpoint technology solutions for clinical trials. This involves guiding the financial aspects of integrating scientific expertise with global scale, contributing to the comprehensive endpoint technology platform. Alexander Brito's financial acumen supports pharmaceutical, biotechnology, and medical device partners by ensuring sound financial practices that underpin their regulatory pursuits. The Chief Financial Officer's role is integral to the financial stability required for the Trial Anywhere approach and the consistent delivery of high-quality clinical evidence across North America, Europe, and the Asia Pacific.

Nayan Nanavati, the Chief Operating Officer at Clario, oversees the company's global operational execution and efficiency. Nanavati's responsibilities include ensuring the seamless delivery of Clario's leading endpoint technology solutions for clinical trials, integrating scientific expertise with global scale. This involves managing the operational aspects of the comprehensive endpoint technology platform that supports pharmaceutical, biotechnology, and medical device partners in transforming lives. Nayan Nanavati's focus is on optimizing the Trial Anywhere approach, enabling the efficient generation of rich clinical evidence across decentralized, hybrid, and site-based trial models. The Chief Operating Officer's strategic oversight ensures high-quality clinical evidence delivery across Clario's operations in North America, Europe, and the Asia Pacific region.

Angelo Stortini, the Chief Operating Officer & Senior VP at Clario, manages the day-to-day operational functions and drives strategic initiatives for enhanced efficiency. Stortini's role is pivotal in ensuring the effective deployment of Clario's endpoint technology solutions within the clinical trial landscape, blending scientific rigor with expansive global reach. This involves overseeing the operational execution of the comprehensive endpoint technology platform, empowering pharmaceutical, biotechnology, and medical device partners to achieve significant milestones. Angelo Stortini's operational leadership supports the successful implementation of the Trial Anywhere methodology, facilitating the collection of robust clinical evidence across decentralized, hybrid, and site-based trial models. The Chief Operating Officer & Senior VP's focus remains on maintaining operational excellence across Clario's global presence in North America, Europe, and the Asia Pacific.

Matthew Borer, the Director - Strategic Chief Revenue Officer Partnerships at Clario, cultivates and manages key revenue-generating partnerships. Borer's strategic focus is on expanding Clario's market reach and revenue streams through collaborative initiatives, directly supporting the company's mission to provide leading endpoint technology solutions for clinical trials. This involves forging alliances that leverage Clario's scientific expertise and global scale, enhancing the impact of its comprehensive endpoint technology platform. Matthew Borer's efforts are crucial for empowering pharmaceutical, biotechnology, and medical device partners by creating synergistic opportunities that accelerate clinical trial success. The Director - Strategic Chief Revenue Officer Partnerships' work ensures the effective commercialization of the Trial Anywhere approach across North America, Europe, and the Asia Pacific.

Todd Rudo, the Chief Medical Officer at Clario, provides critical medical and scientific leadership for the company's endpoint technology solutions in clinical trials. Rudo's expertise ensures that Clario's platform aligns with the highest scientific standards and regulatory requirements, fusing scientific expertise with global operational capabilities. This involves guiding the medical strategy behind the comprehensive endpoint technology platform, enabling pharmaceutical, biotechnology, and medical device partners to achieve transformative outcomes. Todd Rudo's clinical insights are essential for the successful implementation of the Trial Anywhere approach, facilitating the generation of scientifically sound and rich clinical evidence across decentralized, hybrid, and site-based trial models. The Chief Medical Officer's direction ensures the medical integrity of Clario's offerings across North America, Europe, and the Asia Pacific.